An immunotherapy turbocharger?; New targets for diabetes, antivenom, chemo resistance;

> New research from the Francis Crick Institute indicates that adding aspirin could turbocharge immunotherapies. Release

> A study at the University of Iowa points to the mitochondrial pyruvate carrier as critical for controlling glucose production in the liver, making it a potential new diabetes drug target. Release

> Investigators at Imperial College London are studying a new therapy that they believe has great potential for preventing motion sickness. Release

> An international group of scientists believe they are on track to developing a less expensive antivenom treatment. Release

> Investigators at UC San Diego say they have found a new pathway and drug that could be used to prevent resistance to chemotherapy and radiation. Release

Suggested Articles

A newfound link between BMAL1, a protein involved in circadian rhythms, and triple-negative breast cancer could point to new treatment strategies.

Combining a DYRK1A inhibitor with popular GLP-1 receptor agonists regenerates insulin-producing beta cells, Mount Sinai scientists found.

Arming a peptide taken from the virus that causes foot-and-mouth disease in cows with the payload tesirine shows promise against pancreatic cancer.